2021.03.24
I-Mab to Host 2021 R&D Day
Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts.
2021.03.19
I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
I-Mab today filed a prospectus supplement with the SEC to register 19,050,555 ordinary shares, including ordinary shares represented by ADSs of I-Mab, held by Gaoling Fund, L.P. and YHG Investment, L.P..
2021.03.11
I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
I-Mab today announced that a poster highlighting the mechanistic differentiation and preclinical research for uliledlimab will be presented at the 2021AACR Annual Meeting taking place virtually April 10 – 15, 2021.
2021.03.10
I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
I-Mab today announced the signing of two new collaborations that sets in motion a discovery initiative to drive innovation and pipeline growth.
2021.03.03
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
Conference Call Scheduled for March 29 at 8:00 a.m. ET with Pre-Registration Required.
2021.02.25
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin alfa in Pediatric Patients with Growth Hormone Deficiency
I-Mab today announced that the first patient has been dosed in the phase 3 pivotal trial for eftansomatropin alfa as a weekly treatment for pediatric growth hormone deficiency in China.
2021.02.24
I-Mab Announces Upcoming Participation at March Conferences
I-Mab today announced its participation in conferences in March.
2021.02.10
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
I-Mab today announced that the CDE of the China NMPA has cleared the IND application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, and PK/PD of TJ210/MOR210 monotherapy in patients with advanced solid tumors.
2021.02.09
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
A registered follow-on public offering by certain pre-IPO shareholders of 3,283,950 ADSs of I-Mab has priced on February 8, 2021 at a public offering price of US$54.0 per ADS.
2021.02.05
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Selling Shareholders of I-Mab
I-Mab today announced the commencement of a proposed registered underwritten public offering by certain selling shareholders of American depositary shares, each 10 ADSs representing 23 ordinary shares of the Company.